Daniela Semedo, PhD,  —

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

Articles by Daniela Semedo

Cystic Fibrosis Compound to Stabilize CFTR Protein Advances in Clinical Study

Nivalis Therapeutics, Inc., recently announced an expanded clinical development plan for N91115, the company’s first-in-class stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, which is defective in patients with cystic fibrosis (CF). An independent Data Monitoring Committee (DMC) completed a review of interim safety results from the ongoing…

Cystic Fibrosis Trust Helps Launch CF Exercise Research Center with £750,000 Grant

An innovative research center providing tailored physical activity and exercise regimens for young people with cystic fibrosis (CF) has been launched with support for the Cystic Fibrosis Trust. The center will benefit from the skills of an international team of specialists, led by Professor Craig Williams and Dr. Alan Barker from the University of Exeter, U.K.,…

Phase 3 Trial of Inhaled Antibiotic to Treat CF-related Lung Infections Supported by $20M in New Financing

Savara Pharmaceuticals recently announced that it has closed a $20 million Series C financing round, which will be used to advance a pivotal Phase 3 clinical trial of AeroVanc (vancomycin hydrochloride inhalation powder), the first dry powder inhaled antibiotic being developed for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis…

XENiOS Invests $2.6M in New Company, XOR-Labs Toronto, Focused on Improving Donor Lungs for Transplant

XENiOS, a privately held medical device company specializing in minimally invasive lung-and-heart assistance, recently announced it has invested $2.6 million in  XOR-Labs Toronto, a spin-off of Toronto General Hospital at University Health Network (UHN) that is working to make more donor lungs available to patients needing transplants because of injuries…

Kalydeco Fails to Gain FDA Approval as CF Treatment for Specific Residual Mutations

Vertex Pharmaceuticals Incorporated recently announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) to its supplemental New Drug Application (sNDA) for Kalydeco (ivacaftor) as a treatment for cystic fibrosis patients ages 2 and older with one of 23 residual function mutations in the cystic fibrosis transmembrane conductance…

Potential CF Treatment for Antibiotic-Resistant Infections Seeks EU Orphan Drug Designation

Arch Biopartners, Inc, announced that it recently submitted an orphan drug designation application to the European Medicines Authority (EMA) for its product AB569, a potential treatment of pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF). The EMA is now reviewing the application, and the Committee for Orphan Medicinal Products…